FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer

On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm

Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news